Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myomo, Inc. (NYSE American: MYO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Myomo is a wearable medical robotics company that develops and markets MyoPro myoelectric orthoses for individuals with neuromuscular disorders and upper-limb paralysis, and its filings offer detailed insight into how this business is structured and financed.
Through documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, Myomo reports information on revenue from MyoPro devices, gross margin, operating expenses, cash position and risk factors related to reimbursement, financing, product development and regulatory approvals. These filings also describe the company’s focus on its MyoPro product line, its relationships with orthotics and prosthetics providers and the Veterans Health Administration, and its dependence on third-party payers such as Medicare Part B and private insurers.
Current reports on Form 8-K document specific material events. For example, Myomo has filed 8-Ks describing a Loan and Security Agreement that provides term loans secured by a lien on the company’s assets, including intellectual property, together with associated warrants to purchase common stock and potential conversion rights. Another 8-K outlines a salary-for-restricted stock units program for certain executives. These filings explain key terms such as interest-only periods, maturity dates, financial covenants and equity-related features.
On Stock Titan, users can view these filings as they are made available from EDGAR and use AI-powered summaries to understand complex sections, including capital structure provisions, debt covenants, warrant terms and equity compensation arrangements. The page also surfaces Form 4 and other ownership-related filings, helping users monitor insider transactions and changes in beneficial ownership alongside the company’s broader financial and operational disclosures.
Myomo, Inc. (MYO) reported insider share purchases by a director. On 11/20/2025, the director bought 4,902 shares of common stock in the open market at $0.72 per share, and on 11/21/2025 bought an additional 2,535 shares at $0.72 per share. After these transactions, the director beneficially owned 481,857 shares of Myomo common stock in direct ownership. The purchases were disclosed on a Form 4 filed for a single reporting person.
Myomo, Inc. director reports open-market share purchases on a Form 4. The reporting person bought 4,000 shares of Myomo common stock on 11/18/2025 at a price of $0.7345 per share in a single open-market transaction. On 11/19/2025, an additional 385 shares were purchased at a weighted average price of $0.765 per share. Following these transactions, the reporting person beneficially owned 75,748 shares directly and 479 shares indirectly through an immediate family member, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.
Myomo, Inc. received an amended Schedule 13G reporting that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively beneficially own 9.9% of Myomo’s common stock. The filing references 38,435,524 shares outstanding as of November 3, 2025.
The reported position reflects 3,790,788 shares of common stock and an additional 3,763,258 pre-funded warrants that are subject to a 9.99% “blocker”, which prevents exercises that would push ownership above that level. As a result, the warrants were not exercisable as of the event date, and the reporting persons indicate passive intent under Schedule 13G certifications.
Myomo, Inc. reported Q3 2025 results with revenue of $10.09 million, up from $9.21 million a year ago. Gross margin declined to 63.8% from 75.4% as higher material costs, increased manufacturing overhead tied to the new headquarters, and less capitalized overhead weighed on profitability. The quarter’s operating loss was $3.52 million, and net loss was $3.66 million (basic and diluted loss per share $0.09).
For the nine months, revenue reached $29.57 million versus $20.48 million last year, while net loss was $11.76 million. Cash and cash equivalents were $12.55 million at September 30, 2025. Operating cash outflow was $13.37 million year‑to‑date. On the balance sheet, the company had $1.0 million outstanding on its revolving credit line and $3.0 million under its term loan facility.
After quarter‑end, Myomo entered a new loan agreement providing up to $17.5 million in committed capital, with $12.5 million funded on November 4, 2025. Management states current cash and expected cash flows are sufficient to fund operations for at least the next twelve months. Shares outstanding were 38,435,524 as of November 3, 2025.
Myomo, Inc. entered a new senior secured Loan and Security Agreement with Avenue on November 4, 2025, providing committed term loans of up to $17.5 million. The company received $12.5 million at closing (Tranche 1), with up to $5.0 million available between November 4, 2026 and May 4, 2027, subject to no default. By mutual agreement, a discretionary tranche could add up to $10.0 million in 2027. The loans bear interest at 4.75% + WSJ prime (with a prime floor set on the closing date) and mature on June 1, 2029. Interest-only runs for 18 months after closing, extendable six months if Tranche 2 funds. The facility is secured by a senior lien on all assets, including IP.
Prepayment fees are 3.0%/2.0%/1.0% by anniversary, plus a 3.25% final payment fee at maturity or earlier prepayment. Covenants require at least $2.5 million of unrestricted cash, achieving ≥75% of trailing three‑month projected revenue, and limiting trailing six‑month cash burn to the greater of 150% of projected or $2.0 million. The lender may convert up to $3.0 million of Tranche 1 and $1.0 million of Tranche 2 into common stock at 120% of the warrant exercise price and holds a $1.0 million equity participation right. Myomo also issued a warrant to purchase up to $1,312,500 worth of common stock, exercisable at the lesser of $0.96 or the next bona fide equity round price before June 30, 2026, expiring November 4, 2030. A Q3 2025 results press release was furnished as Exhibit 99.1.
Myomo (MYO): Ownership update. Orin Hirschman and affiliated entities filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 523,000 shares of Myomo common stock, representing 1.3% of the class as of 09/30/2025. Mr. Hirschman has sole voting and dispositive power over these shares.
AIGH Capital Management LLC reports 0 shares. The filing indicates ownership of five percent or less of the class and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control.
Myomo, Inc. (MYO) reporting person Paul R. Gudonis, who serves as Chief Executive Officer and a director, reported a gift of 10,000 shares of Myomo common stock on 09/09/2025. The transaction was coded as a disposition at $0 and the filer states it was a bona fide gift with no direct or indirect benefit to the reporting person. After the reported transfer, the reporting person beneficially owns 1,249,013 shares directly. The Form 4 was signed by an attorney-in-fact on 09/11/2025 and discloses the relationship of the reporting person to the issuer as CEO and director.
Myomo, Inc. director Thomas F. Kirk reported an open-market purchase of 50,000 shares of Myomo common stock on 08/25/2025 at an execution price of $1.15 per share. After the transaction the reporting person beneficially owns 474,420 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing states the purchases occurred in multiple lots at $1.15 per share and that the reporting party will provide transaction details to the SEC upon request. No derivative transactions, dispositions, or additional securities classes are reported.
Myomo, Inc. director Thomas F. Kirk reported open-market purchases of 50,000 shares of Myomo common stock on 08/18/2025 at an execution price of $1.10 per share (two transactions at $1.10 each). Following these purchases, Mr. Kirk beneficially owned 424,420 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing states the purchases were open-market trades and that details can be provided to the SEC upon request.
Myomo, Inc. insider purchase: The company's CEO and director, Paul R. Gudonis, made open-market purchases totaling 50,000 shares of Myomo common stock on 08/15/2025 at a volume-weighted average price of $0.9459 per share (individual trade prices ranged from $0.9289 to $0.9687). After these purchases, Mr. Gudonis beneficially owned 1,259,013 shares directly. The filing was signed by an attorney-in-fact on behalf of the reporting person.